公开(公告)号：US08177361B2

公开(公告)日：2012-05-15

申请号：US12524310

申请日：2008-01-25

Applicant: Rainer Sessner ,  Werner Mueller ,  Dietmar Uttenweiler ,  Edda Wehner

Inventor： Rainer Sessner ,  Werner Mueller ,  Dietmar Uttenweiler ,  Edda Wehner

IPC: G02C1/00

CPC classification number: G02C7/14 ,  G02B27/0172 ,  G02B2027/015 ,  G02B2027/0178 ,  G02C7/061 ,  G02C7/086

Abstract: The invention relates particularly to a spectacle lens having a first and a second surface, wherein at least the first surface of the spectacle lens has a major portion zone and at least one prism zone. The major portion zone of the first surface, together with the opposing second surface of the spectacle lens, forms a major portion of the spectacle lens, which is designed for vision in at least a predetermined distance. The prism zone of the first surface, together with the opposing second surface of the spectacle lens, forms a prism portion, which is designed and arranged such that an optical image of a display is formed at a predetermined virtual distance in front of the eyes of the spectacle wearer. The invention further relates to spectacles, which comprise the spectacle lens, and to a method and apparatuses for calculating or optimizing and producing the spectacle lens.

Abstract translation: 本发明尤其涉及具有第一和第二表面的眼镜镜片，其中眼镜镜片的至少第一表面具有主要部分区域和至少一个棱镜区域。 第一表面的主要部分区域与眼镜镜片的相对的第二表面一起形成眼镜镜片的主要部分，其被设计用于至少预定距离的视力。 第一表面的棱镜区域与眼镜镜片的相对的第二表面一起形成棱镜部分，其被设计和布置成使得显示器的光学图像形成在眼睛前方的预定虚拟距离处 眼镜佩戴者。 本发明还涉及包括眼镜镜片的眼镜以及用于计算或优化和制造眼镜镜片的方法和装置。

公开(公告)号：US08138189B2

公开(公告)日：2012-03-20

申请号：US12727269

申请日：2010-03-19

Applicant: Daniel Hunziker ,  Chrisitan Lerner ,  Werner Mueller ,  Ulrike Obst Sander ,  Philippe Pflieger ,  Pius Waldmeier

Inventor： Daniel Hunziker ,  Chrisitan Lerner ,  Werner Mueller ,  Ulrike Obst Sander ,  Philippe Pflieger ,  Pius Waldmeier

IPC: A61K31/497

CPC classification number: C07D241/12 ,  C07D207/34 ,  C07D213/30 ,  C07D213/61 ,  C07D213/64 ,  C07D215/14 ,  C07D217/16 ,  C07D241/42 ,  C07D333/38 ,  C07D401/12 ,  C07D413/12 ,  C07D471/02

Abstract: The present invention relates to compounds of formula I wherein R.sup.1a to R.sup.1e and R.sup.2 to R.sup.5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.

Abstract translation: 本发明涉及式I化合物，其中R 1和R 2与R.sup.5的定义如说明书和权利要求书及其药学上可接受的盐。 该化合物是可用于治疗和/或预防糖尿病，血脂异常，肥胖，高血压，心血管疾病，肾上腺不平衡或抑郁症等疾病的糖皮质激素受体拮抗剂。

公开(公告)号：US07770383B2

公开(公告)日：2010-08-10

申请号：US10533779

申请日：2003-10-31

Applicant: Sebastian Kaefer ,  Werner Mueller ,  Andreas Herr ,  Andreas Lacroix

Inventor： Sebastian Kaefer ,  Werner Mueller ,  Andreas Herr ,  Andreas Lacroix

IPC: F01N3/00

CPC classification number: F01N3/2066 ,  B01D53/9431 ,  B01J8/002 ,  F01N2610/02 ,  F01N2610/08 ,  F01N2610/12 ,  F01N2610/1406 ,  Y02A50/2325 ,  Y02T10/24

Abstract: In a device for dosing and transporting dry urea, e.g., for implementing the SCR method in a motor vehicle, the device includes a storage vessel containing the dry urea in the form of pellets, the wall of the storage vessel having an opening to which a transport line is connected on the outer side. The device also includes a compressed air nozzle which is arranged inside the storage vessel at a distance from the opening, is oriented towards the opening, and may be supplied with compressed air, and a portioning element having an upper side oriented towards the inside of the storage vessel and a lower side opposite the wall of the storage vessel. At least one continuous channel having a larger cross section than the dimensions of the pellets connects the upper side and the lower side in order to form at least one receiving element for the pellets.

Abstract translation: 在用于计量和运输干尿素的装置中，例如用于在机动车辆中实施SCR方法的装置中，该装置包括容纳小丸形式的干燥尿素的储存容器，储存容器的壁具有开口 输送线在外侧连接。 该装置还包括压缩空气喷嘴，该压缩空气喷嘴布置在存储容器内部距开口一定距离处，朝向开口定向，并且可以被供应压缩空气，并且具有朝向内部的上侧的分配元件 储存容器和与储存容器的壁相对的下侧。 至少一个具有比所述丸粒的尺寸更大的横截面的连续通道连接上侧和下侧，以形成用于粒料的至少一个接收元件。

公开(公告)号：US07745477B2

公开(公告)日：2010-06-29

申请号：US11698221

申请日：2007-01-25

Applicant: Aurelia Conte ,  Holger Kuehne ,  Thomas Luebbers ,  Patrizio Mattei ,  Cyrille Maugeais ,  Werner Mueller ,  Philippe Pflieger

Inventor： Aurelia Conte ,  Holger Kuehne ,  Thomas Luebbers ,  Patrizio Mattei ,  Cyrille Maugeais ,  Werner Mueller ,  Philippe Pflieger

IPC: A61K31/415 ,  C07D231/10

CPC classification number: C07C233/66 ,  C07C233/65 ,  C07C233/73 ,  C07C2601/02 ,  C07C2601/04 ,  C07D213/40 ,  C07D213/61 ,  C07D213/81 ,  C07D213/82 ,  C07D231/16 ,  C07D239/28 ,  C07F7/081

Abstract: Compounds of formula I wherein R1, R2, R4, R5, A, B, D and n are as defined, and pharmaceutically acceptable salts thereof, processes for their preparation, their use as pharmaceuticals and pharmaceutical compositions comprising them.

Abstract translation: 其中R 1，R 2，R 4，R 5，A，B，D和n如所定义的式I化合物及其药学上可接受的盐，其制备方法，它们作为药物的用途和包含它们的药物组合物。

公开(公告)号：US07579369B2

公开(公告)日：2009-08-25

申请号：US11801727

申请日：2007-05-10

Applicant: Alexander Mayweg ,  Hans Peter Marty ,  Werner Mueller ,  Robert Narquizian ,  Werner Neidhart ,  Philippe Pflieger ,  Stephan Roever

Inventor： Alexander Mayweg ,  Hans Peter Marty ,  Werner Mueller ,  Robert Narquizian ,  Werner Neidhart ,  Philippe Pflieger ,  Stephan Roever

IPC: A61K31/40 ,  C07D233/64

CPC classification number: C07D231/12 ,  C07D207/34 ,  C07D233/56 ,  C07D233/90 ,  C07D249/08 ,  C07D401/04 ,  C07D405/04 ,  C07D405/12 ,  C07D409/12

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

Abstract translation: 本发明涉及其中R 1，R 2，R 3，R 4，R 5，R 6，m和X如说明书和权利要求书中所定义的式（I）化合物及其药学上可接受的盐。 该化合物可用于治疗和/或预防与调节CB1受体相关的疾病。

公开(公告)号：US07347546B2

公开(公告)日：2008-03-25

申请号：US10568677

申请日：2004-08-17

Applicant: Gregor Esser ,  Werner Mueller ,  Herbert Pfeiffer ,  Helmut Altheimer ,  Peter Baumbach ,  Walter Haimerl ,  Jochen Brosig

Inventor： Gregor Esser ,  Werner Mueller ,  Herbert Pfeiffer ,  Helmut Altheimer ,  Peter Baumbach ,  Walter Haimerl ,  Jochen Brosig

IPC: G02C7/02

CPC classification number: G02C7/02

Abstract: The invention relates to a method of producing a single-strength spectacle lens while taking into account an individual spectacle wearer's data, the single-strength spectacle lens having a rotationally symmetrical base surface and a rotationally symmetrical aspherical or atoric prescription surface, comprising the following steps: Acquisition of an individual spectacle wearer's data; selection of a spectacle lens blank with a predetermined base surface from a group of spectacle lens blanks; and calculation and optimization of the prescription surface while taking into account at least a part of the individual spectacle wearer's data in addition to an adaptation of the dioptric effect by the prescription surface to the spectacle wearer's prescription. The invention also relates to a corresponding system for producing a single-strength spectacle lens and to an individual single-strength spectacle lens.

Abstract translation: 本发明涉及一种考虑到个别眼镜佩戴者的数据的单强度眼镜镜片的制造方法，单眼镜片具有旋转对称的基面和旋转对称的非球面或立体处方面，其包括以下步骤 ：获取个人眼镜佩戴者的数据; 从一组眼镜镜片坯料中选择具有预定基面的眼镜镜片坯料; 以及处方面的计算和优化，同时考虑到个别眼镜佩戴者的数据的至少一部分，以及处方表面的屈光效应对眼镜佩戴者的处方的适应性。 本发明还涉及用于生产单强度眼镜镜片和单独的单强度眼镜镜片的相应系统。

公开(公告)号：US07294644B2

公开(公告)日：2007-11-13

申请号：US10743642

申请日：2003-12-22

Applicant: Alexander Mayweg ,  Hans Peter Marty ,  Werner Mueller ,  Robert Narquizian ,  Werner Neidhart ,  Philippe Pflieger ,  Stephan Roever

Inventor： Alexander Mayweg ,  Hans Peter Marty ,  Werner Mueller ,  Robert Narquizian ,  Werner Neidhart ,  Philippe Pflieger ,  Stephan Roever

IPC: A61K31/40 ,  A61K31/4164

CPC classification number: C07D231/12 ,  C07D207/34 ,  C07D233/56 ,  C07D233/90 ,  C07D249/08 ,  C07D401/04 ,  C07D405/04 ,  C07D405/12 ,  C07D409/12

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

Abstract translation: 本发明涉及式（I）的化合物，其中R 1，R 2，R 3，R 4， >，R 5，R 6，m和X如说明书和权利要求书中所定义，及其药学上可接受的盐。 该化合物可用于治疗和/或预防与调节CB1受体相关的疾病。

公开(公告)号：US07119248B1

公开(公告)日：2006-10-10

申请号：US08226168

申请日：1994-04-12

Applicant: Klaus Rajewsky ,  Werner Mueller ,  Juergen Roes

Inventor： Klaus Rajewsky ,  Werner Mueller ,  Juergen Roes

IPC: C12P21/08 ,  A01K67/027 ,  A61K39/00 ,  C12N5/06 ,  C07K16/18

CPC classification number: C12N15/8509 ,  A01K67/0276 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/01 ,  A61K38/00 ,  C07K16/00 ,  C07K16/2803 ,  C07K16/4283 ,  C07K2317/20 ,  G01N33/56966

Abstract: This invention provides novel methods of obtaining autologous monoclonal antibodies (AMABs) to self-antigens or homologs thereof. The method involves obtaining a genetically engineered host animal that does not biosynthesize at least one epitope of the antigen and utilizes the lack of self-tolerance of the host to the epitope to produce antibodies specific to the antigen. The invention also encompasses the AMABs produced by the methods. The invention further encompasses methods of isolating cells comprising the use of such AMABs that have specificity for a cell surface antigen.

Abstract translation: 本发明提供了获得自身抗原或其同系物的自体单克隆抗体（AMAB）的新方法。 该方法包括获得不生物合成抗原的至少一个表位的遗传工程宿主动物，并利用宿主对表位的自身耐受性不足以产生抗原特异性抗体。 本发明还包括通过这些方法生产的AMAB。 本发明还包括分离细胞的方法，所述方法包括使用对细胞表面抗原具有特异性的这种AMAB。

公开(公告)号：US20060063758A1

公开(公告)日：2006-03-23

申请号：US11272207

申请日：2005-11-10

Applicant: Michael Klug ,  Patrizio Mattei ,  Werner Mueller ,  Werner Neidhart ,  Matthias Nettekoven ,  Philippe Pflieger ,  Jean-Marc Plancher

Inventor： Michael Klug ,  Patrizio Mattei ,  Werner Mueller ,  Werner Neidhart ,  Matthias Nettekoven ,  Philippe Pflieger ,  Jean-Marc Plancher

IPC: A61K31/55 ,  A61K31/4709 ,  C07D401/02

CPC classification number: C07D401/04 ,  C04B35/632 ,  C07D215/42 ,  C07D401/12 ,  C07D405/14

Abstract: Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Abstract translation: 式I化合物

公开(公告)号：US20060030613A1

公开(公告)日：2006-02-09

申请号：US11197688

申请日：2005-08-04

Applicant: Aurelia Conte-Mayweg ,  Holger Kuehne ,  Thomas Luebbers ,  Cyrille Maugeais ,  Werner Mueller ,  Philippe Pflieger

Inventor： Aurelia Conte-Mayweg ,  Holger Kuehne ,  Thomas Luebbers ,  Cyrille Maugeais ,  Werner Mueller ,  Philippe Pflieger

IPC: A61K31/416 ,  A61K31/405 ,  C07D403/02

CPC classification number: C07D209/30

Abstract: The present invention relates to compounds of formula (I): wherein —X—Y—, R1 to R11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.

Abstract translation: 本发明涉及式（I）化合物：其中-XY-，R 1至R 11和n如说明书和权利要求中所定义，并且药学上可接受的 的盐。 该化合物可用于治疗和/或预防由CETP抑制剂介导的疾病。